Ed T. Buurman received his Ph.D. degree in Chemistry from the University of Amsterdam, followed by postdoctoral research at the University of Chicago (IL) and University of Aberdeen (U.K.). He then joined the collaborative antifungal drug discovery effort of Scriptgen Pharmaceuticals with Hoechst Marion Roussel, currently part of Sanofi. Three years later he moved to AstraZeneca R&D Boston where he has since worked in various capacities on many aspects of antimicrobial drug discovery, ranging from target validation to lead optimization and support of NDA filings. Most of this work has been published to benefit the wider antibacterial drug discovery community.